KMDA — KAMADA LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1567529 ·
Last close
$8.43
Market Cap
$486.36M
52W High
$8.59
52W Low
$6.85
ADV30
107,191
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 45,240,000 | 19,116,000 | 6,953,000 | 4,132,000 | 383,021,000 | 32,922,000 | 123,634,000 |
| Dec 2025 | 44,678,000 | 16,967,000 | 3,551,000 | 3,562,000 | 378,710,000 | 75,469,000 | 109,640,000 |
| Sep 2025 | 47,010,000 | 19,762,000 | 7,816,000 | 5,296,000 | 377,210,000 | 71,997,000 | 111,978,000 |
| Jun 2025 | 44,754,000 | 18,929,000 | 7,071,000 | 7,376,000 | 368,173,000 | 65,985,000 | 108,219,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$25,712,000
Investing CF
$-49,576,000
Financing CF
$-18,908,000
CapEx
$-9,351,000
Dividends Paid
$-11,534,000
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-27,363,000
Inventory
$85,437,000
Receivables
$40,651,000
ST Investments
$40,225,000
EBIT TTM
$23,105,000
Pretax Income TTM
$22,245,000
Interest Exp TTM
$860,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$181,682,000
EBITDA
$38,910,000
Free Cash Flow
$11,081,875
Enterprise Value
$347,488,128
Total Cash
$73,147,000
Total Debt
$11,641,000
Shares Out
57,694,272
Trailing EPS
$0.38
Book Value
$4.50
ROE
8.0%
ROA
4.2%
Div Yield
3.53%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 180,460,000 | 26,233,000 | 20,198,000 | 378,710,000 | 109,640,000 | — | 25,490,000 |
| Dec 2024 | 160,953,000 | 20,051,000 | 14,462,000 | 372,255,000 | 112,791,000 | — | 47,594,000 |
| Dec 2023 | 142,519,000 | 10,064,000 | 8,284,000 | 354,907,000 | 110,886,000 | — | 4,315,000 |
| Dec 2022 | 129,339,000 | 4,532,000 | -2,321,000 | 322,379,000 | 146,359,000 | — | 28,586,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.60
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $8.53 · call volume: 30 · put volume: 1
Expected Move to 2026-11-20:
±$2.67
(31.36%) —
implied range
$5.85 –
$11.20
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | $487.03M | $16.36 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $488.55M | $4.58 | — |
| RZLT | Rezolute, Inc. | $482.42M | $5.01 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $482.05M | $9.39 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $481.01M | $7.28 | — |
News headlines (Yahoo Finance, 1h cache)
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
2026-08-17 11:00 · Yahoo
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
2026-08-14 16:45 · Yahoo
KMDA or PRTA: Which Is the Better Value Stock Right Now?
2026-08-14 15:40 · Yahoo
Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet
2026-08-14 13:55 · Yahoo
Should Value Investors Buy Kamada (KMDA) Stock?
2026-08-13 13:40 · Yahoo
Kamada Ltd (KMDA) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
2026-08-12 23:03 · Yahoo
Kamada Q2 Earnings Call Highlights
2026-08-12 15:04 · Yahoo
Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-08-12 13:30 · Yahoo
Kamada Announces Planned Transition of Chief Financial Officer
2026-08-12 11:00 · Yahoo
Curious about Kamada (KMDA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
2026-08-07 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.